Precidian ETFs Trust - Novo Nordisk A/S (B Shares) ADRhedged Receivables

Precidian ETFs Trust - Novo Nordisk A/S (B Shares) ADRhedged posts a receivables of $820M as of September 2016. That compares with $580M in the prior-year period — up 42.4% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Precidian ETFs Trust - Novo Nordisk A/S (B Shares) ADRhedged's receivables was $580M. The latest reading is $820M — a 42.4% year-over-year increase (period ending September 2016). Use the history and growth charts on this page for a longer lookback.

Receivables is one piece of Precidian ETFs Trust - Novo Nordisk A/S (B Shares) ADRhedged's financial statement story. At $820M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for NVOH's receivables usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Precidian ETFs Trust - Novo Nordisk A/S (B Shares) ADRhedged's other metric pages and overview cover the third.